BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29020356)

  • 1. A common missense variant of LILRB5 is associated with statin intolerance and myalgia.
    K Siddiqui M; Maroteau C; Veluchamy A; Tornio A; Tavendale R; Carr F; Abelega NU; Carr D; Bloch K; Hallberg P; Yue QY; Pearson ER; Colhoun HM; Morris AD; Dow E; George J; Pirmohamed M; Ridker PM; Doney ASF; Alfirevic A; Wadelius M; Maitland-van der Zee AH; Chasman DI; Palmer CNA;
    Eur Heart J; 2017 Dec; 38(48):3569-3575. PubMed ID: 29020356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CKM and LILRB5 are associated with serum levels of creatine kinase.
    Dubé MP; Zetler R; Barhdadi A; Brown AM; Mongrain I; Normand V; Laplante N; Asselin G; Zada YF; Provost S; Bergeron J; Kouz S; Dufour R; Diaz A; de Denus S; Turgeon J; Rhéaume E; Phillips MS; Tardif JC
    Circ Cardiovasc Genet; 2014 Dec; 7(6):880-6. PubMed ID: 25214527
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Siddiqui MK; Veluchamy A; Maroteau C; Tavendale R; Carr F; Pearson E; Colhoun H; Morris AD; George J; Doney A; Pirmohamed M; Alfirevic A; Wadelius M; Maitland van der Zee AH; Ridker PM; Chasman DI; Palmer CNA;
    Circ Cardiovasc Genet; 2017 Aug; 10(4):. PubMed ID: 28790154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia.
    Khine H; Yuet WC; Adams-Huet B; Ahmad Z
    Am Heart J; 2016 Sep; 179():1-9. PubMed ID: 27595674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial.
    Murphy WA; Lin N; Damask A; Schwartz GG; Steg PG; Szarek M; Banerjee P; Fazio S; Manvelian G; Pordy R; Shuldiner AR; Paulding C
    Circ Genom Precis Med; 2022 Jun; 15(3):e003503. PubMed ID: 35543701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common Statin Intolerance Variants in
    Melhem AL; Chourasia MK; Bigossi M; Maroteau C; Taylor A; Pola R; Dawed AY; Tornio A; Palmer CNA; Siddiqui MK
    Front Genet; 2021; 12():713181. PubMed ID: 34659336
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk identification and possible countermeasures for muscle adverse effects during statin therapy.
    Magni P; Macchi C; Morlotti B; Sirtori CR; Ruscica M
    Eur J Intern Med; 2015 Mar; 26(2):82-8. PubMed ID: 25640999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia.
    Harris LJ; Thapa R; Brown M; Pabbathi S; Childress RD; Heimberg M; Braden R; Elam MB
    J Clin Lipidol; 2011; 5(4):299-307. PubMed ID: 21784376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cholesterol-lowering effect of statins is modified by
    Tornio A; Bigossi M; Siddiqui MK; Kennedy G; Melhem A; Chourasia MK; Maroteau C; Pola R; Chasman DI; Doney ASF; Palmer CNA
    Front Pharmacol; 2023; 14():1090010. PubMed ID: 36998609
    [No Abstract]   [Full Text] [Related]  

  • 10. Increased creatine kinase with statin treatment may identify statin-associated muscle symptoms.
    Taylor BA; Panza G; Thompson PD
    Int J Cardiol; 2016 Apr; 209():12-3. PubMed ID: 26874453
    [No Abstract]   [Full Text] [Related]  

  • 11. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
    Hubáček JA; Dlouhá D; Adámková V; Zlatohlavek L; Viklický O; Hrubá P; Češka R; Vrablík M
    Med Sci Monit; 2015 May; 21():1454-9. PubMed ID: 25992810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects.
    Ramakumari N; Indumathi B; Katkam SK; Kutala VK
    Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S120-S125. PubMed ID: 30595243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance.
    Bigossi M; Maroteau C; Dawed AY; Taylor A; Srinivasan S; Melhem AL; Pearson ER; Pola R; Palmer CNA; Siddiqui MK
    Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):536-545. PubMed ID: 37253618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leucocyte immunoglobulin-like receptor subfamily-B5 (LILRB5) genetic variation and statin-associated muscle symptoms: another piece in a puzzling puzzle.
    März W; Laufs U
    Eur Heart J; 2017 Dec; 38(48):3576-3578. PubMed ID: 29059353
    [No Abstract]   [Full Text] [Related]  

  • 15. Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patients.
    Calza L; Magistrelli E; Colangeli V; Borderi M; Contadini I; Bon I; Re MC; Viale P
    AIDS; 2017 Mar; 31(5):681-688. PubMed ID: 28060020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants.
    Lönnberg KI; Tornio A; Hirvensalo P; Keskitalo J; Mustaniemi AL; Kiiski JI; Filppula AM; Niemi M
    Pharmacogenet Genomics; 2023 Sep; 33(7):153-160. PubMed ID: 37490620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptomatic myositis-myalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle.
    Glueck CJ; Abuchaibe C; Wang P
    Med Hypotheses; 2011 Oct; 77(4):658-61. PubMed ID: 21802861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin Intolerance: the Clinician's Perspective.
    Stulc T; Ceška R; Gotto AM
    Curr Atheroscler Rep; 2015 Dec; 17(12):69. PubMed ID: 26490078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features related to statin-associated muscle symptoms.
    Ochs-Balcom HM; Nguyen LM; Ma C; Isackson PJ; Luzum JA; Kitzmiller JP; Tarnopolsky M; Weisman M; Christopher-Stine L; Peltier W; Wortmann RL; Vladutiu GD
    Muscle Nerve; 2019 May; 59(5):537-543. PubMed ID: 30549046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
    Mora S; Glynn RJ; Hsia J; MacFadyen JG; Genest J; Ridker PM
    Circulation; 2010 Mar; 121(9):1069-77. PubMed ID: 20176986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.